

domain of said transducer component, and wherein said antibody does not substantially stimulate said B cell antigen receptor;

wherein contact with said antibody: (1) causes a dissociation of said mIg extracellular ligand binding component from said transducer component when said components are associated with each other prior to contact with said antibody; or (2) inhibits association of said mIg extracellular ligand binding component with said transducer component when said components are dissociated from each other prior to contact with said antibody.

4. (Once Amended) The method of Claim 1, wherein said antibody inhibits association of said extracellular ligand binding component with said transducer component when said components are dissociated from each other.

5. (Once Amended) The method of Claim 4, wherein said antibody selectively binds to a portion of said transducer component that contacts a portion of said extracellular ligand binding component when said receptor is bound by its natural ligand, thereby inhibiting contact of said transducer component with said extracellular ligand binding component.

6. (Once Amended) The method of Claim 4, wherein said antibody selectively binds to a portion of said transducer component which contacts a portion of said extracellular ligand binding component that is phosphorylated when said receptor is bound by its natural ligand, thereby inhibiting phosphorylation of said extracellular ligand binding component.

8. (Once Amended) The method of Claim 1, wherein said antibody is monovalent.

10. (Once Amended) The method of Claim 1, wherein said antibody is divalent.

12. (Once Amended) The method of Claim 1, wherein said antibody is a bi-specific antibody comprising:

a. a first portion which binds to said receptor and: (1) causes a dissociation of said extracellular ligand binding component from said transducer component when said components are associated with each other prior to contact with said antibody; or (2) inhibits association of said extracellular ligand binding component with said transducer component when said components are dissociated from each other prior to contact with said antibody; and

B4
SVB
CY: covid

b. a second portion which selectively binds to a cell surface molecule expressed by a cell which expresses said receptor.

13. (Reiterated) The method of Claim 12, wherein said second portion binds to a cell surface molecule which is expressed by an autoreactive B cell.

14. (Reiterated) The method of Claim 12, wherein said second portion binds to an antigen binding region of said B cell antigen receptor.

18. (Once Amended) The method of Claim 1, wherein said mIg is selected from the group consisting of IgD and IgM.

11 19. (Once Amended) The method of Claim 1, wherein said B cell antigen receptor selectively binds to an antigen associated with an autoimmune disease.

12 20. (Once Amended) The method of Claim 1, wherein said B cell antigen receptor selectively binds to an antigen associated with a graft cell.


21. (Once Amended) The method of Claim 1, wherein said receptor is expressed by a cell selected from the group consisting of an autoreactive B cell, a B cell comprising a B cell antigen receptor that selectively binds to an antigen on a graft, a B cell lymphoma and a chronic lymphocytic leukemia cell.

14 22. (Once Amended) The method of Claim 1, wherein said antibody is administered to a patient that has an autoimmune disease selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, insulin dependent diabetes mellitis, multiple sclerosis, myasthenia gravis, Grave's disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, post-streptococcal glomerulonephritis, and polyarteritis nodosa.

15 20. (Once Amended) The method of Claim 1, wherein said antibody is administered to a patient by way of a therapeutic composition comprising a pharmaceutically acceptable carrier and said antibody.

31. (Reiterated) The method of Claim 30, wherein said therapeutic composition is administered *in vivo*.

32. (Reiterated) The method of Claim 30, wherein said therapeutic composition is administered *ex vivo*.

 33. (Once Amended) The method of Claim 1, wherein said antibody is contacted with said receptor in an *in vitro* assay.